MediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million.
Latest MediWound news
We have not published a story on MediWound yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $4.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about MediWound
Has MediWound raised money recently?
Our latest story on this, dated Mar 5, 2026: "MediWound reports $53.6 million in cash after $30.0 million registered direct offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of MediWound?
MediWound Ltd. trades under the ticker MDWD on NASDAQ.
Where is MediWound listed?
MediWound Ltd. is listed on NASDAQ. Our directory also records these other listings: LS:A110TG.
What is the SEC CIK of MediWound?
The SEC Central Index Key (CIK) for MediWound Ltd. is 1593984. Its filings are on SEC EDGAR.
How many shares does MediWound have outstanding?
12,835,148 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05.
Which country or territory is MediWound listed under?
Our directory records MediWound Ltd. under Israel.
What does MediWound do?
Our directory classifies MediWound Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of MediWound?
The ISIN recorded for MediWound Ltd. is IL0011316309.
Does aibio.space cover MediWound?
aibio.space lists MediWound Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is MediWound incorporated?
SEC records list its state or country of incorporation as L3.
What was MediWound's revenue last year?
$17.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is MediWound profitable?
MediWound Ltd. reported a net loss of $23.9 million for the fiscal year ended Dec 31, 2025, and used $16.1 million of cash in operations, per its annual report to the SEC.
How much does MediWound spend on research and development?
$14.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does MediWound have?
$4.8 million in cash at Dec 31, 2025, per its 20-F.
What is the latest MediWound (MDWD) stock news?
Our latest story on MediWound, dated Mar 5, 2026: "MediWound reports $53.6 million in cash after $30.0 million registered direct offering". MediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million. Source.
Investor discussion: MediWound
Members talk about MediWound (MDWD). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at MediWound, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MDWD on TradingView.
SEC filings and registration
SEC name
MediWound Ltd.
CIK
1593984
Industry (SIC)
Medicinal Chemicals & Botanical Products (2833)
US tickers
MDWD (Nasdaq)
State or country of incorporation
L3
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
42 HAYARKON STREET, YAVNE, Israel, 8122745
Phone
972779714100
Shares outstanding
12,835,148 as of 2025-12-31 (20-F filed 2026-03-05)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
MediWound Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MDWD, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio